TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01895348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol-remifentanil
Description: Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine-remifentanil
Description: Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
Study: NCT04024267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eurythmy therapy
Description: Mind-body therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CoordiFit
Description: Fitness training
Study: NCT04563806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI-guided surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo spinal surgery
Study: NCT01898143

Intervention type: OTHER
Group type: OTHER
Intervention: Whole body vibration

Intervention type: OTHER
Group type: OTHER
Intervention: Whole body vibration
Study: NCT04172402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1
Description: Intervention is administered to patients in this Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intervention is administered to patients in this Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intervention is administered to patients in this Arm.
Study: NCT02918903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal caries removal
Description: the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete caries removal
Description: the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
Study: NCT02985073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veritas®
Description: Biologic mesh

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIGR®
Description: Non biologic mesh
Study: NCT01210495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Axitinib \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo \[tablet, 1 mg, 5 mg\] will be given twice daily \[BID\] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
Study: NCT01446237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%
Description: over the counter acne system
Study: NCT01046851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nopan
Description: Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
Study: NCT04127084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 Inhibition
Description: Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 Inhibition
Description: Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
Study: NCT01046851

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a manner similar to the active comparator
Study: NCT00588211

Intervention type: BEHAVIORAL
Intervention: Interviews
Description: 45-minute individual interviews after the conclusion of their dental appointment

Intervention type: BEHAVIORAL
Intervention: focus group
Description: A focus group of the preliminary cancer-related risk perception item pool.

Intervention type: BEHAVIORAL
Intervention: Survey
Description: Quantitative item analysis of the final item pool.

Intervention type: BEHAVIORAL
Intervention: Survey
Description: A second confirmatory factor analysis.
Study: NCT01117675

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Hospital
Description: A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of Care
Study: NCT04590677

Intervention type: OTHER
Intervention: Samples required from group 1 (procedure within observational study)
Description: * Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs~* Daily Heart rate monitoring (only applicable to a subset of women in group 1)

Intervention type: OTHER
Intervention: Samples required from group 2 (procedure within observational study)
Description: * Weekly maternal blood samples to be taken~* Daily urine samples to be collected~* One rectal swab at the initial visit only~* Weekly vaginal swabs
Study: NCT02464891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Study: NCT02444364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Subjects will receive 90 tablets of 100mg sitagliptin
Study: NCT06309420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryogenic treatment of warts (Pixie CO2)
Description: Treatment of common and plantar warts by cryotherapy treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryogenic treatment of warts (Wortie®)
Description: Treatment of common and plantar warts by cryotherapy treatment.
Study: NCT01914575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mapping with the Acutus Medical System followed by Ablation
Study: NCT01374932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Continuous positive airways pressure (CPAP)
Study: NCT01829178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silymarin
Description: Silymarin 420 mg in 3 divided dose plus standard chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo tablets: 420 mg in 3 divided dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy
Description: All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
Study: NCT04706806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: apple cider vinegar
Description: 2 tablespoons diluted in water taken twice daily with meals

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vinegar pill
Description: one pill taken daily
Study: NCT00692107

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Gray
Description: 68 Gy vs. 78 Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gray
Description: 68 Gy vs. 78 Gy
Study: NCT03064100

Intervention type: OTHER
Intervention: Observational Study
Description: Exclusion from the study
Study: NCT00362713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
Study: NCT02396303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Study: NCT01286168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite (Dakin's Solution)
Description: 10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate disk
Description: Apply one chlorhexidine disk to the intervention drain site(s) and change every three days

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control
Description: Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusive Adhesive Dressing
Description: A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
Study: NCT04285515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumateperone
Description: Lumateperone 42mg oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo oral capsule
Study: NCT02928770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nastent
Description: Use of the device while at home and in the sleep lab
Study: NCT04500600

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT01432561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine bitartrate
Description: 500 mg total, single dose taken orally on visits 2, 3 \& 4 which must occur within a 14 day period.
Study: NCT03740529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV
Study: NCT00868491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel, cisplatin, 5-fluorouracil
Description: docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab, cisplatin
Description: * cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20~* cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)
Study: NCT01332279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polyacrylamide gel electrophoresis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo EBRT

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study: NCT02813005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jet ventilation group
Description: MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Standard ventilation group
Description: apnea made by the anesthesiologist to the request of the radiologist
Study: NCT02407457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AFX EVAR AAA Graft System
Description: Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA Approved EVAR AAA Graft Systems
Study: NCT04630249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to Women and Pregnant and Postpartum People
Description: Participants are enrolled in text message-based screenings with immediate automated feedback, paired with remote care coordination and, if appropriate, referral to telemedicine mental health and substance use disorder treatment services.
Study: NCT02789956

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal vs. external cad cam co/cr framework

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal vs. external cad cam co/cr framework
Study: NCT06157112

Intervention type: OTHER
Intervention: Lifestyle behaviour (exposure in a observational study)
Description: Lifestyle behaviour, including physical activity, sleep duration, alcohol consumption, smoking, cannabis and other illegal drugs
Study: NCT00713661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TachoSil®
Description: Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.~Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy.
Study: NCT00451295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
Study: NCT01786824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydration strategy using saline
Description: For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
Study: NCT04127084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 Inhibition
Description: Dapagliflozine 5-10 mg once daily tablet treatment or Empagliflozin10 mg once daily tablet treatment or Canagliflozin 100 mg once daily tablet treatment
Study: NCT04215185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial LIne
Description: Continuous non-invasive recording of CS6BP will be taken parallel to the recording of an invasive arterial line. ECG data recorded in the ICU will also be collected.
Study: NCT01786824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydration strategy using saline
Description: For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydration strategy using sodium bicarbonate
Description: For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydration strategy using sodium bicarbonate
Description: For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.~For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronarography
Description: All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronarography
Description: All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronarography
Description: All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronarography
Description: All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
Study: NCT02161328

Intervention type: OTHER
Intervention: EIT belt
Study: NCT03525574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX/TEZ/IVA
Description: Fixed-dose combination (FDC) tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT01565200

Intervention type: DRUG
Group type: OTHER
Intervention: T-DM1
Description: 3.6 mg/kg iv every 3 weeks

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 89Zr-trastuzumab
Description: Injection of 89Zr-trastuzumab for HER2 imaging
Study: NCT00472186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will also be administered based on weight.
Study: NCT01254565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Administered intravenously (IV) at the end of hemodialysis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously at the end of hemodialysis
Study: NCT03989635

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: QAW039
Description: QAW039 450mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 450mg
Study: NCT03030547

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SenseWear activity monitor
Description: Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenseWear activity monitor
Description: Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).